Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK

OBJECTIVE: The aim was to determine the cost effectiveness of secukinumab, a fully human interleukin-17A inhibitor, for adults in the UK with active psoriatic arthritis (PsA) who are tumour necrosis factor inhibitor (TNFi) naïve and without concomitant moderate-to-severe psoriasis, and who have resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Buchanan, Vanessa, Sullivan, Will, Graham, Chris, Miles, LaStella, Jugl, Steffen Marc, Gunda, Praveen, Halliday, Anna, Kirkham, Bruce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999172/
https://www.ncbi.nlm.nih.gov/pubmed/29797187
http://dx.doi.org/10.1007/s40273-018-0674-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999172/
https://www.ncbi.nlm.nih.gov/pubmed/29797187
http://dx.doi.org/10.1007/s40273-018-0674-x

Ejemplares similares